Scandinavian ChemoTech

The Board of Scandinavian ChemoTech AB (publ) (”ChemoTech” or the ”Company”) has, with authorisation from the Annual General Meeting on May 16th, 2023, decided on a Rights issue of B-shares for approximately SEK 14.85 million before deduction of issue costs (“The rights issue”). The subscription price has been set to SEK 2.50 per B-share.

Those who are shareholders in ChemoTech on the recorded date of October 16th, 2023, will receive three (3) subscription rights for each share held, regardless of share type. Seven (7) subscription rights entitle the holder to subscribe for one (1) new B-share. All in all, the subscription obligations amount to approximately SEK 6 million, corresponding to approximately 40 percent of the Rights Issue.

The complete executive summary can be found in the document attached to this press release.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.